OncoSil Medical Ltd OSL

Proceeds are earmarked for the commercial rollout of the OncoSil device in Australia and the US.

OncoSil Medical Ltd (ASX:OSL, OTC:OCMLF) has secured US Food and Drug Administration (FDA) approval for its OncoSil™ targeted radiation device to treat distal cholangiocarcinoma (dCCA), giving the company US marketing authorisation and opening an estimated A$80 million annual addressable...

The approval is expected to drive increased clinical adoption and support applications for regulatory approval in other markets.

Pancreatic cancer has long sat among oncology’s most difficult frontiers — a disease where survival rates remain stubbornly low, diagnoses often arrive too late and treatment breakthroughs have historically been limited. That backdrop helps explain why investors responded positively this week...

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...